ES3060149T3 - Dosage forms for tyk2 inhibitors - Google Patents

Dosage forms for tyk2 inhibitors

Info

Publication number
ES3060149T3
ES3060149T3 ES20781719T ES20781719T ES3060149T3 ES 3060149 T3 ES3060149 T3 ES 3060149T3 ES 20781719 T ES20781719 T ES 20781719T ES 20781719 T ES20781719 T ES 20781719T ES 3060149 T3 ES3060149 T3 ES 3060149T3
Authority
ES
Spain
Prior art keywords
bms
pharmaceutical form
amorphous
hpmcas
dispersion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES20781719T
Other languages
English (en)
Spanish (es)
Inventor
Sherif Ibrahim Farag Badawy
Jonathan R Brown
Candice Y Choi
Christoph Gesenberg
Vivienne Gray
John Wynne Jones
Umesh Kestur
Balvinder S Vig
Xiaotian Yin
Christopher A Zordan
Corey Bloom
Ian Yates
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of ES3060149T3 publication Critical patent/ES3060149T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
ES20781719T 2019-09-18 2020-09-18 Dosage forms for tyk2 inhibitors Active ES3060149T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962902218P 2019-09-18 2019-09-18
PCT/US2020/051342 WO2021055652A1 (en) 2019-09-18 2020-09-18 Dosage forms for tyk2 inhibitors

Publications (1)

Publication Number Publication Date
ES3060149T3 true ES3060149T3 (en) 2026-03-25

Family

ID=72670853

Family Applications (2)

Application Number Title Priority Date Filing Date
ES20781719T Active ES3060149T3 (en) 2019-09-18 2020-09-18 Dosage forms for tyk2 inhibitors
ES20781718T Active ES3065958T3 (en) 2019-09-18 2020-09-18 Extended release dosage forms for tyk2 inhibitors

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES20781718T Active ES3065958T3 (en) 2019-09-18 2020-09-18 Extended release dosage forms for tyk2 inhibitors

Country Status (21)

Country Link
US (4) US12521390B2 (cg-RX-API-DMAC10.html)
EP (3) EP4031110B1 (cg-RX-API-DMAC10.html)
JP (4) JP7719770B2 (cg-RX-API-DMAC10.html)
KR (2) KR20220066105A (cg-RX-API-DMAC10.html)
CN (8) CN119424434A (cg-RX-API-DMAC10.html)
AU (2) AU2020349524B2 (cg-RX-API-DMAC10.html)
BR (2) BR112022004216A2 (cg-RX-API-DMAC10.html)
CA (2) CA3151369A1 (cg-RX-API-DMAC10.html)
DK (1) DK4031110T3 (cg-RX-API-DMAC10.html)
ES (2) ES3060149T3 (cg-RX-API-DMAC10.html)
FI (1) FI4031110T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20260058T1 (cg-RX-API-DMAC10.html)
IL (3) IL291452B1 (cg-RX-API-DMAC10.html)
LT (1) LT4031110T (cg-RX-API-DMAC10.html)
MX (4) MX2022003146A (cg-RX-API-DMAC10.html)
PL (1) PL4031110T3 (cg-RX-API-DMAC10.html)
PT (1) PT4031110T (cg-RX-API-DMAC10.html)
RS (1) RS67803B1 (cg-RX-API-DMAC10.html)
SI (1) SI4031110T1 (cg-RX-API-DMAC10.html)
SM (1) SMT202600127T1 (cg-RX-API-DMAC10.html)
WO (2) WO2021055652A1 (cg-RX-API-DMAC10.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL291452B1 (en) * 2019-09-18 2026-06-01 Bristol Myers Squibb Co Dosage forms for TYK2 inhibitors
US20240325388A1 (en) * 2020-09-18 2024-10-03 Bristol-Myers Squibb Company Dosage forms for tyk2 inhibitors comprising swellable cores
US12668594B2 (en) 2020-12-23 2026-06-30 Sudo Biosciences Limited TYK2 inhibitors and uses thereof
IL305119A (en) 2021-02-19 2023-10-01 Sudo Biosciences Ltd Tyk2 inhibitors and uses thereof
TW202302583A (zh) 2021-02-19 2023-01-16 英商蘇多生物科學有限公司 Tyk2抑制劑及其用途
KR20230159421A (ko) 2021-02-19 2023-11-21 수도 바이오사이언시즈 리미티드 Tyk2 억제제 및 이의 용도
KR20240065283A (ko) 2021-09-23 2024-05-14 브리스톨-마이어스 스큅 컴퍼니 Tyk2 억제제를 사용하여 탈모 장애를 치료하는 방법
KR20240111312A (ko) 2021-10-25 2024-07-16 카이메라 쎄라퓨틱스 인코포레이티드 Tyk2 분해제 및 이의 용도
JP2024539703A (ja) * 2021-10-28 2024-10-29 ブリストル-マイヤーズ スクイブ カンパニー デュークラバシチニブの局所製剤
WO2023181075A1 (en) * 2022-03-24 2023-09-28 Dr. Reddy's Laboratories Limited Amorphous solid dispersions of deucravacitinib and processes for the preparation thereof
AR128868A1 (es) * 2022-03-25 2024-06-19 Nimbus Lakshmi Inc Formulaciones de inhibidor de tyk2 y métodos para elaborarlas
WO2024176263A1 (en) * 2023-02-22 2024-08-29 Cipla Limited Deucravacitinib amorphous solid dispersions and polymorphs thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT901786E (pt) 1997-08-11 2007-08-07 Pfizer Prod Inc Disperções farmacêuticas sólidas com biodisponibilidade melhorada
EP1027885B1 (en) * 1999-02-09 2008-07-09 Pfizer Products Inc. Basic drug compositions with enhanced bioavailability
ATE433318T1 (de) 1999-02-10 2009-06-15 Pfizer Prod Inc Osmotisches system zur verabreichung von wirkstoffen, die feste amorphe dispersionen enthalten
US6706283B1 (en) 1999-02-10 2004-03-16 Pfizer Inc Controlled release by extrusion of solid amorphous dispersions of drugs
ES2310164T3 (es) 1999-02-10 2009-01-01 Pfizer Products Inc. Dispositivo de liberacion controlada por la matriz.
DK1242055T3 (da) 1999-12-23 2008-07-21 Pfizer Prod Inc Hydrogelstyret doseringsform til lægemidler
MXPA03011784A (es) 2001-06-22 2004-04-02 Pfizer Prod Inc Composiciones farmaceuticas de dispersiones de farmacos y polimeros neutros.
BR0307332A (pt) 2002-02-01 2004-12-07 Pfizer Prod Inc Formas de dosagem farmacêuticas de liberação controlada de um inibidor da proteìna de transferência do éster de colesterol
WO2008084698A1 (ja) 2006-12-28 2008-07-17 Astellas Pharma Inc. タクロリムス徐放性医薬組成物
CN101152158B (zh) 2007-08-21 2010-05-26 浙江大学 一种药物的双层芯渗透泵片的制备方法
SMT202000093T1 (it) 2009-06-16 2020-03-13 Pfizer Forme di dosaggio di apixaban
US9095585B2 (en) 2011-07-21 2015-08-04 Bristol-Myers Squibb Company Bioavailable compositions of amorphous piperidinyl compounds
TWI673051B (zh) * 2012-09-11 2019-10-01 美商梅維森前列腺療法有限責任公司 恩雜魯它脈(enzalutamide)之調和物
EP2895150A1 (en) 2012-09-11 2015-07-22 Bend Research, Inc. Methods for making pharmaceutical solid dosage forms of spray-dried dispersions
WO2014068402A2 (en) 2012-09-28 2014-05-08 Oncoethix Sa Pharmaceutical formulation containing thienotriazolodiazepine compounds
HRP20220766T1 (hr) * 2012-11-08 2022-09-16 Bristol-Myers Squibb Company Amidom-supstituirani heterociklički spojevi korisni kao modulatori il-12, il-23 i/ili ifn alfa odgovora
JP6634368B2 (ja) 2013-03-14 2020-01-22 アムジエン・インコーポレーテツド 複素環式化合物及びそれらの使用
LT3601268T (lt) 2017-03-30 2021-05-25 Bristol-Myers Squibb Company 6-(ciklopropanamido)-4-((2-metoksi-3-(1-metil-1h-1,2,4-triazol-3-il)fenil)amino)-n-(metil-d3)piridazino-3-karboksamido gavimo būdas
CN118994118A (zh) 2018-05-31 2024-11-22 百时美施贵宝公司 化合物的结晶形式
US12171764B2 (en) 2018-06-20 2024-12-24 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with a JAK or other kinase inhibitor
IL291452B1 (en) * 2019-09-18 2026-06-01 Bristol Myers Squibb Co Dosage forms for TYK2 inhibitors
US20240325388A1 (en) * 2020-09-18 2024-10-03 Bristol-Myers Squibb Company Dosage forms for tyk2 inhibitors comprising swellable cores

Also Published As

Publication number Publication date
MX2025014307A (es) 2026-01-07
EP4706778A3 (en) 2026-05-20
FI4031110T3 (fi) 2026-03-10
BR112022004216A2 (pt) 2022-05-31
CN119424433A (zh) 2025-02-14
CN119424435A (zh) 2025-02-14
IL291452B1 (en) 2026-06-01
US20230255964A1 (en) 2023-08-17
EP4031110A1 (en) 2022-07-27
JP7812785B2 (ja) 2026-02-10
JP2022548688A (ja) 2022-11-21
HRP20260058T1 (hr) 2026-02-27
PT4031110T (pt) 2026-02-03
EP4031109A1 (en) 2022-07-27
US20260083734A1 (en) 2026-03-26
IL291452A (en) 2022-05-01
US20260083733A1 (en) 2026-03-26
WO2021055652A1 (en) 2021-03-25
MX2022003150A (es) 2022-04-06
IL328425A (en) 2026-07-01
CA3151137A1 (en) 2021-03-25
MX2025014308A (es) 2026-01-07
JP2022548687A (ja) 2022-11-21
BR112022004550A2 (pt) 2022-05-31
JP7719770B2 (ja) 2025-08-06
AU2020349524A1 (en) 2022-03-31
DK4031110T3 (da) 2026-03-23
EP4031109B1 (en) 2026-02-18
EP4031109C0 (en) 2026-02-18
LT4031110T (lt) 2026-02-25
JP2025163082A (ja) 2025-10-28
MX2022003146A (es) 2022-04-06
CN114727949A (zh) 2022-07-08
PL4031110T3 (pl) 2026-03-30
EP4706778A2 (en) 2026-03-11
IL291453A (en) 2022-05-01
SMT202600127T1 (it) 2026-05-12
US12521390B2 (en) 2026-01-13
AU2020349524B2 (en) 2026-05-07
CN119745885A (zh) 2025-04-04
AU2020348783B2 (en) 2026-04-16
WO2021055651A1 (en) 2021-03-25
CN114727948A (zh) 2022-07-08
CN119700772A (zh) 2025-03-28
AU2020348783A1 (en) 2022-03-31
ES3065958T3 (en) 2026-05-08
CN119700773A (zh) 2025-03-28
US20220331315A1 (en) 2022-10-20
CN119424434A (zh) 2025-02-14
KR20220066105A (ko) 2022-05-23
CA3151369A1 (en) 2021-03-25
RS67803B1 (sr) 2026-03-31
EP4031110B1 (en) 2025-12-24
JP2026090315A (ja) 2026-06-02
SI4031110T1 (sl) 2026-03-31
KR20220066310A (ko) 2022-05-24

Similar Documents

Publication Publication Date Title
US20260083734A1 (en) Dosage forms for tyk2 inhibitors
Panakanti et al. Impact of excipient interactions on drug bioavailability from solid dosage forms
KR102225416B1 (ko) 엔잘루타마이드 제제
CN103998037B (zh) 对高熔点疏水性化合物具有改进的生物利用度的药物组合物
ES2616115T3 (es) Forma farmacéutica oral de liberación controlada que comprende oxicodona
KR20050084316A (ko) 경구고형의약
HK40119662A (en) Dosage forms for tyk2 inhibitors
HK40119663A (en) Dosage forms for tyk2 inhibitors
HK40119664A (zh) Tyk2抑制剂的剂型
Bello Physiochemical and drug release properties of Liquisolid formulations in comparison to their physical mixture counterparts
PAUL MASTER OF PHARMACY
Gholami Preparation and Evaluation of Sustained Release Formulation for an Anti Hypertensive Drug